TVTX at a glance
Travere Therapeutics, Inc. (TVTX, SEC CIK 1438533) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 21, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Travere Therapeutics, Inc. (TVTX) reported revenue of $490.7 million (up 110.5% from FY2024) and a net loss of $25.5 million. Diluted EPS was -$0.29.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Travere Therapeutics, Inc. (TVTX) shares worth $2.3 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Dube Eric M on September 17, 2026 of 6,802 shares at $64.95 per share.
- In the last 90 days, TVTX insiders reported 0 open-market purchases ($0) and 46 open-market sales ($67.0M) on Form 4, a net sale of $67.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $490.7M
- +110.5% vs prior year
- Insiders · 90 days
- 0 buys · 46 sells
- Net −$67.0M
- 13F holders
- 32 funds
- $2.3B · +4 vs prior quarter
- Latest 8-K
- Sep 21, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Developing, manufacturing outsourced, and commercializing pharmaceutical products, including marketed drug FILSPARI and pipeline candidates
- New emphasis on pegtibatinase Phase 3 HARMONY Study resumed in 2026 after voluntary enrollment pause in Sept 2024 due to manufacturing scale-up issues
- Strategic reliance on third-party manufacturers with increased risks from global supply chain disruptions, tariffs, BIOSECURE Act export restrictions, and geopolitical tensions
- Employee base and operations expanded significantly over five years, especially sales force growth to support FILSPARI commercial launch in U.S.
- Noteworthy: The BIOSECURE Act (effective Dec 2025) imposes U.S. federal restrictions on biotechnology equipment/services from “biotechnology companies of concern,” impacting supplier relationships
Risk Factors
- Cybersecurity risk management overseen by Nominating / Corporate Governance Committee reporting to board
- Cybersecurity incident team with cross-functional expertise including IT, legal, compliance, and privacy functions
- Incident response process escalates cyber incidents to executive team and board when necessary
- Regular management reports on cybersecurity risks delivered to governance committee and board
Management Discussion & Analysis
- Revenue specifics and YoY changes not disclosed in provided MD&A section
- Profitability or margin figures absent; no actual % margins reported
- Best segment: FILSPARI US approval and European market launch with $57.5M milestone payments received
- Worst segment impact: Thiola sales affected by multiple generic approvals, leading to material adverse impact
- Cash flow & capital allocation: $210M upfront and $25M milestone payments from bile acid assets sale; restructuring saves ~$25M annually from 2024
- Forward outlook: FDA sNDA review for FILSPARI in FSGS continuing with April 13, 2026 PDUFA date; Phase 3 HARMONY study enrollment resumed Q1 2026 after manufacturing pause
AI summary of the TVTX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $169.6M, up $55.1M YoY from $114.4M, driven by FILSPARI sales
- FILSPARI revenue $141.1M, up $69.2M YoY; tiopronin $20.3M, down $2.7M
- Operating expenses $165.6M, up $38.5M YoY; R&D $60.3M and SG&A $96.1M
- Cash deployment: $112.5M upfront payment for civorebrutinib license in July 2026
- HARMONY enrollment restarted in Q1 2026; topline pegtibatinase data anticipated in second half of 2027
Risk Factors
- FSGS approval in April 2026 expanded FILSPARI commercialization risk to a new indication
- Commercial execution risk increased with FSGS launch requiring further U.S. sales-force training
- MFN pricing executive order issued May 2025 could materially reduce product pricing
- Sole-source manufacturers for FILSPARI and Thiola heighten supply-disruption exposure
- France reimbursement dispute includes approximately $6.2 million paid while appeal continues
AI summary of the TVTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO transition effective December 1, 2026, with Bradley Campbell replacing Eric Dube and joining the Board
- Campbell brings Amicus CEO and commercialization experience following BioMarin’s April 2026 acquisition of Amicus
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 4, 2026, with detailed results in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 U.S. net product sales rose to $161.4M from $94.8M, led by FILSPARI sales of $141.1M, up 96% year-over-year
- FSGS launch and IgAN growth generated 2,012 new patient start forms, supporting continued FILSPARI demand expansion
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CAO/PAO Sandra Calvin plans retirement after expected February 2027 Form 10-K filing
- Vice President, Controller John Torell expected successor, supporting continuity in financial reporting
AI summaries of TVTX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TVTX
Don't miss the next TVTX filing
- Alerts as it files. A push when TVTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TVTX, by share count.
- Ask anything. An AI agent that reads every TVTX filing and answers with sources.
TVTX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Dube Eric M | M | Sep 17, 2026 | 108,493 | - |
| Heerma Peter | M | Sep 17, 2026 | 8,282 | - |
| Dube Eric M | M | Sep 17, 2026 | 108,493 | $23.34 |
| Dube Eric M | Sell | Sep 17, 2026 | 6,802 | $64.95 |
| Heerma Peter | Sell | Sep 17, 2026 | 8,282 | $65.07 |
| Dube Eric M | Sell | Sep 17, 2026 | 101,691 | $64.59 |
| Heerma Peter | M | Sep 17, 2026 | 8,282 | $22.40 |
| Heerma Peter | M | Sep 16, 2026 | 100,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $233.2M | $490.7M |
| Operating Income | -$388.1M | -$323.8M | -$62.8M |
| Net Income | -$111.4M | -$321.5M | -$25.5M |
| Op. Margin | - | -138.9% | -12.8% |
| Net Margin | - | -137.9% | -5.2% |
| Balance Sheet | |||
| Total Assets | $788.9M | $594.1M | $605.2M |
| Equity | $200.8M | $59.1M | $114.8M |
| ROE | -55.5% | -544.3% | -22.2% |
| Per Share | |||
| EPS | $-1.50 | $-4.08 | $-0.29 |
| Cash Flow | |||
| Operating CF | - | -$237.5M | $37.8M |
| CapEx | $668K | - | - |
Source: XBRL data in Travere Therapeutics, Inc. (TVTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TVTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $2.32B |
| Q1 2026 | 28 | $1.20B |
| Q4 2025 | 26 | $1.59B |
| Q3 2025 | 25 | $768.7M |
| Q2 2025 | 26 | $482.4M |
| Q1 2025 | 22 | $455.3M |
| Q4 2024 | 19 | $438.1M |
| Q3 2024 | 15 | $144.2M |
- Bank of America Corp+3.22M (+240%)
- T. Rowe Price Group+913.8K (+226%)
- D.E. Shaw & Co+603.9K (+72%)
- BlackRock+228.6K (+3%)
- Morgan Stanley+127.6K (+42%)
- FMR LLC (Fidelity)−3.87M (-35%)
- State Street Corp−703.8K (-14%)
- Goldman Sachs Group−184.4K (-11%)
- Vanguard Portfolio Management LLC−167.5K (-10%)
- Renaissance Technologies LLC−133.7K (-7%)
- Raymond James Financial+292.4K
- Millennium Management+84.7K
- Ameriprise Financial+7.6K
- Principal Financial Group+6.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 193 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TVTX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 21, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| SC 13G | Aug 12, 2026 | - | - | |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 9, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 8-K | May 21, 2026 | - | Analysis | |
| 4 | May 21, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
TVTX SEC filings: frequently asked questions
Are TVTX insiders buying or selling?
In the last 90 days, Travere Therapeutics, Inc. (TVTX) officers, directors and 10% owners reported no open-market purchases and 46 open-market sales worth $67.0 million by 9 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TVTX stock?
As of June 30, 2026, the largest Travere Therapeutics, Inc. (TVTX) holders among the 13F filers tracked by SignalX were BlackRock ($455.7 million), FMR LLC (Fidelity) ($403.2 million), Bank of America Corp ($259.5 million), State Street Corp ($241.8 million), Vanguard Capital Management LLC ($233.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TVTX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Travere Therapeutics, Inc. (TVTX) reported revenue of $490.7 million (up 110.5% from FY2024) and a net loss of $25.5 million. Diluted EPS was -$0.29. The figures come from the XBRL data in the 10-K.
What are the main risks in TVTX's latest 10-K?
In the 10-K filed February 19, 2026, Travere Therapeutics, Inc. (TVTX) flagged: Cybersecurity risk management overseen by Nominating / Corporate Governance Committee reporting to board. Cybersecurity incident team with cross-functional expertise including IT, legal, compliance, and privacy functions. (AI summary of the Risk Factors section.)
What did TVTX report in its latest 8-K?
Travere Therapeutics, Inc. (TVTX) filed an 8-K on September 21, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). CEO transition effective December 1, 2026, with Bradley Campbell replacing Eric Dube and joining the Board.
What are the latest TVTX SEC filings?
Travere Therapeutics, Inc. (TVTX) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 21, 2026 and a Form 4 insider filing on September 17, 2026.
What is TVTX's SEC CIK number?
Travere Therapeutics, Inc. (TVTX)'s SEC Central Index Key (CIK) is 1438533. EDGAR lists every TVTX filing under that number.
Ask anything about TVTX
The research agent reads TVTX's filings, financials, insider trades and 13F holders, then answers with sources.